IGC IGC Pharma
- 0.5538
- +0.0338+6.50%
- 0.5800
- +0.0262+4.73%
IGC Pharma News
'DEA Appears To Question Marijuana's Medical Value Despite Rescheduling Recommendation' - Marijuana Moment
'DEA Appears To Question Marijuana's Medical Value Despite Rescheduling Recommendation' - Marijuana Moment
6.7 Million Americans Live With Alzheimer's - IGC Pharma Believes They Deserve Treatment Options...
Newsweek Reporter Kevin Sabet Says On X "I Can Now Say With Full Confidence That The Administrator Of DEA, Anne Milgram, Did Not Sign The Rescheduling Order, Breaking With Five Decades Of Precedent And Established Law And Regulations (Two Confidential...
Newsweek Reporter Kevin Sabet Says On X "I Can Now Say With Full Confidence That The Administrator Of DEA, Anne Milgram, Did Not Sign The Rescheduling Order, Breaking With Five Decades Of Precedent An
'Declassifying Cannabis Still Leaves Pot Stocks In Limbo' - Wall Street Journal
'Declassifying Cannabis Still Leaves Pot Stocks In Limbo' - Wall Street Journal
Shares of Cannabis-related Stocks Are Trading Higher Following Reports Suggesting the DEA Plans to Reclassify Cannabis as a Less Dangerous Drug.
Shares of Cannabis-related Stocks Are Trading Higher Following Reports Suggesting the DEA Plans to Reclassify Cannabis as a Less Dangerous Drug.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersAkanda (NASDAQ:AKAN) shares moved upwards by 69.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. NanoVibronix (NASDAQ:NAOV) shares moved upwar
Shares of Cannabis Stocks Are Trading Higher Following a Report Indicating the DEA Is Moving to Reclassify Marijuana as a Less Dangerous Drug.
Shares of Cannabis Stocks Are Trading Higher Following a Report Indicating the DEA Is Moving to Reclassify Marijuana as a Less Dangerous Drug.
DEA Moving To Reclassify Marijuana As Less Dangerous Drug
DEA Moving To Reclassify Marijuana As Less Dangerous Drug
IGC Pharma Announces Interim Results For IGC-AD1 In Reducing Alzheimer's Agitation; Results Indicate That IGC-AD1 Clinically Reduced Agitation Compared To Placebo
IGC Pharma Announces Interim Results For IGC-AD1 In Reducing Alzheimer's Agitation; Results Indicate That IGC-AD1 Clinically Reduced Agitation Compared To Placebo
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersClene (NASDAQ:CLNN) shares moved upwards by 54.9% to $0.48 during Tuesday's after-market session. The company's market cap stands at $61.6 million. Talphera (NASDAQ:TLPH) shares moved upwards b
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
Tuesday, IGC Pharma Inc (NYSE:IGC) released interim data from its Phase 2 clinical trial of IGC-AD1 for agitation in dementia associated with Alzheimer's.The data demonstrates a clinically significant
IGC Pharma Announces Interim Phase 2 Data Showing IGC-AD1 Achieved Secondary Endpoint And Demonstrated A Clinical Reduction In Alzheimer's Agitation At Week Two
IGC Pharma Announces Interim Phase 2 Data Showing IGC-AD1 Achieved Secondary Endpoint And Demonstrated A Clinical Reduction In Alzheimer's Agitation At Week Two
'FDA Head Says There's 'No Reason For DEA To Delay' Rescheduling Marijuana' - Marijuana Moment
'FDA Head Says There's 'No Reason For DEA To Delay' Rescheduling Marijuana' - Marijuana Moment
IGC Pharma Adds Advisor in Artificial Intelligence
IGC Pharma, Inc. (IGC) Soars in After Market After Positive Alzheimer's Research Results
IGC Pharma, Inc. (NYSE: IGC) witnessed an unprecedented surge in its stock price following the release of encouraging phase 2 results in Alzheimer's research. The initial uptick of 19.5% during trading hours was just the beginning of an exhilarating journey, as the afterhours session saw an additional 15% spike, propelling the stock beyond its 52-week ...
'GOP Senators Tell DEA To Reject Marijuana Rescheduling, Arguing It Would Violate International Treaties' - Marijuana Moment
Three Republican senators are urging the Drug Enforcement Administration (DEA) to reject the top federal health agency's marijuana rescheduling recommendation, arguing that it would put the U.S. out o
IGC Pharma Announces $3 Million Unregistered Private Placement of Its Common Stock
IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited ("Bradbury"), a leading asset management
'Three In Five Americans Want Congress To Pass Marijuana Banking Reform, American Bankers Associations Poll Finds Amid Renewed Push' - Marijuana Moment
A new poll from the American Bankers Association (ABA) shows that roughly three out of five Americans support allowing marijuana industry access to the banking system—a finding that comes amid a renew
EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
In a massive stride towards Alzheimer's treatment, IGC Pharma (NYSE:IGC) recently revealed promising interim results for their pioneering drug, IGC-AD1, aimed at mitigating agitation in Alzheimer's pa
IGC Pharma, Inc. Common Shares Resume Trade
IGC Pharma, Inc. Common Shares Resume Trade
Analysis
Price Target
No Data
